Dudediligence.

Xeris Biopharma Holdings, Inc

XERSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$54.3MSep ’24$60.1MDec ’24$60.1MMar ’25$71.5MJun ’25$74.4MSep ’25$85.8MDec ’25$83.1MMar ’26$92.1MJun ’26
Net income, by quarter
−$15.7MSep ’24−$5.1MDec ’24−$9.2MMar ’25−$1.9MJun ’25$621,000Sep ’25$11.1MDec ’25$2.2MMar ’26−$31.1MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$49.6M$110.2M$163.9M$203.1M$291.8M
Operating income−$115.2M−$81.9M−$44.0M−$33.6M$24.9M
Net income−$122.7M−$94.7M−$62.3M−$54.8M$554,000
Operating cash flow−$95.5M−$102.9M−$47.0M−$37.0M$28.6M
Free cash flow−$96.6Mnone on filenone on filenone on filenone on file
Cash$67.3M$122.0M$67.4M$71.6M$111.0M
Debt$88.1M$187.1M$190.9M$232.1M$220.3M
Shares outstanding124.9M136.3M138.1M149.4M166.2M